Catalog Products » GPA hFc Chimera, Human
Manual
Manual
COAs

GPA hFc Chimera, Human

Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
$340.00
Z05366-100

Ask us a question
Product Introduction
Species Human
Protein Construction
GPA (Ser20-Glu91)
Accession # AAA52768.1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity GPA hFc Chimera, Human immobilized on CM5 Chip can bind Anti­-GPA Antibody, hFc Tag in SPR assay (Biacore S200). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 34.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 45-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

GPA HFc Chimera, Human

The purity of GPA hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »

GPA HFc Chimera, Human

GPA hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

GPA HFc Chimera, Human

Anti-GPA Antibody immobilized on CM5 Chip can bind GPA hFc Chimera, Human, hFc Tag with an affinity constant of 0.72 μM as determined in SPR assay (Biacore T200). »

<
>

Background
Target Background Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
Synonyms Glycophorin-A; Glycophorin A; PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.